These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 6097273)
1. Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in essential hypertension. Felder K; Witte PU Arzneimittelforschung; 1984; 34(10B):1452-4. PubMed ID: 6097273 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498). Schölkens BA; Becker RH; Kaiser J Arzneimittelforschung; 1984; 34(10B):1417-25. PubMed ID: 6097268 [TBL] [Abstract][Full Text] [Related]
3. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers. Witte PU; Metzger H; Eckert HG; Irmisch R Arzneimittelforschung; 1984; 34(10B):1448-51. PubMed ID: 6097272 [TBL] [Abstract][Full Text] [Related]
4. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats. Unger T; Fleck T; Ganten D; Lang RE; Rettig F Arzneimittelforschung; 1984; 34(10B):1426-30. PubMed ID: 6097269 [TBL] [Abstract][Full Text] [Related]
5. Synthesis of a highly active angiotensin converting enzyme inhibitor: 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498). Teetz V; Geiger R; Henning R; Urbach H Arzneimittelforschung; 1984; 34(10B):1399-401. PubMed ID: 6097264 [TBL] [Abstract][Full Text] [Related]
6. Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension. Lenz T; Distler A; Haller H; Meyer-Sabellek W; Wilp C; Tansey MJ; Eckert HG; Metzger H; Irmisch R; Philipp T Arzneimittelforschung; 1986 Nov; 36(11):1693-6. PubMed ID: 3028438 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498). Becker RH; Schölkens BA; Metzger M; Schulze KJ Arzneimittelforschung; 1984; 34(10B):1411-6. PubMed ID: 6097267 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat. Bünning P Arzneimittelforschung; 1984; 34(10B):1406-10. PubMed ID: 6097266 [TBL] [Abstract][Full Text] [Related]
9. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor. Metzger H; Maier R; Sitter C; Stern HO Arzneimittelforschung; 1984; 34(10B):1402-6. PubMed ID: 6097265 [TBL] [Abstract][Full Text] [Related]
10. Determination of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) and its hydrolysis product in serum and urine. Hajdú P; Schmidt D; Bomm M; Hack L; Keller A Arzneimittelforschung; 1984; 34(10B):1431-5. PubMed ID: 6097270 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. Eckert HG; Badian MJ; Gantz D; Kellner HM; Volz M Arzneimittelforschung; 1984; 34(10B):1435-47. PubMed ID: 6097271 [TBL] [Abstract][Full Text] [Related]
12. Acute, subchronic and chronic toxicity of the new angiotensin converting enzyme inhibitor ramipril. Donaubauer HH; Mayer D Arzneimittelforschung; 1988 Jan; 38(1):14-20. PubMed ID: 2966628 [TBL] [Abstract][Full Text] [Related]
13. Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man. Böhm RO; van Baak MA; Rahn KH Eur J Clin Pharmacol; 1986; 30(5):541-7. PubMed ID: 3019702 [TBL] [Abstract][Full Text] [Related]
14. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat. Caspritz G; Alpermann HG; Schleyerbach R Arzneimittelforschung; 1986 Nov; 36(11):1605-8. PubMed ID: 3028436 [TBL] [Abstract][Full Text] [Related]
15. A radioimmunoassay for the angiotensin converting enzyme inhibitor ramipril and its active metabolite. Eckert HG; Münscher G; Oekonomopulos R; Strecker H; Urbach H; Wissmann H Arzneimittelforschung; 1985; 35(8):1251-6. PubMed ID: 3000393 [TBL] [Abstract][Full Text] [Related]
16. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril. Predel HG; Düsing R; Bäcker A; Kipnowski J; Kramer HJ Am J Cardiol; 1987 Apr; 59(10):143D-148D. PubMed ID: 3034023 [TBL] [Abstract][Full Text] [Related]
17. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension. Karlberg BE; Lindström T; Rosenqvist U; Ohman KP Am J Cardiol; 1987 Apr; 59(10):104D-109D. PubMed ID: 3034016 [TBL] [Abstract][Full Text] [Related]
18. Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients. de Leeuw PW; Lugtenburg PL; van Houten H; Looman JH; Birkenhäger WH J Cardiovasc Pharmacol; 1985; 7(6):1161-5. PubMed ID: 2418304 [TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus. Janka HU; Nuber A; Mehnert H Arzneimittelforschung; 1990 Apr; 40(4):432-5. PubMed ID: 2141472 [TBL] [Abstract][Full Text] [Related]
20. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important. Wenting GJ; Blankestijn PJ; Poldermans D; van Geelen J; Derkx FH; Man in't Veld AJ; Schalekamp MA Am J Cardiol; 1987 Apr; 59(10):92D-97D. PubMed ID: 3034041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]